Egrifta

(tesamorelin)

Egrifta 2 MG Injection

NO BOXED WARNING

Dosage & administration

* The recommendations in this prescribing information only apply to EGRIFTA SV (tesamorelin for injection) 2 mg per vial formulation. For recommendations for tesamorelin for injection 1 mg per vial formulation, see the EGRIFTA prescribing information. These two formulations and strengths have differences in the dosage, the number of vials required to prepare a dose, reconstitution instructions, and storage requirements. .
* The dose of EGRIFTA SV is 1.4 mg (0.35 mL of the reconstituted solution) injected subcutaneously once daily.
* Inject EGRIFTA SV into the abdomen, rotating injection sites.
* Use only the diluent provided, Sterile Water for Injection, USP, to reconstitute EGRIFTA SV.
* Reconstitute one vial of lyophilized powder with 0.5 mL of diluent. Mix by rolling the vial gently in your hands for 30 seconds. Do not shake.
* Inspect the reconstituted vial visually for particulate matter and discoloration. Use only if the solution is clear, colorless and without particulate matter.
* Administer 0.35 mL of EGRIFTA SV immediately following reconstitution and throw away any unused solution and diluent.

drug label

Egrifta prescribing information

Contact Medical Science Liaison Report Adverse Event

prior authorization

Egrifta prior authorization resources

Most recent Egrifta prior authorization forms

View By Payer

Verified: Nov 26, 2023Cigna - Egrifta Prior Authorization Form

Learn More

Benefits investigation

Egrifta Support Enrollment Form

Learn More

financial assistance

Egrifta financial assistance options

Co-pay savings program

commercial only

Enroll in Patient Savings Program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

patient education

Egrifta patient education

Getting started on Egrifta

Instructions For Use: Reduction of Excess Belly Fat In HIV+ With Lipodystrophy

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

To share resource; ask patient to:

1.Pull out phone

2.Open camera

3.Scan QR code with camera

4.Tap link

Patient toolkit

About Egrifta SV

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Patient Stories

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Doctor Discussion Guide

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Learn More

Egrifta FAQs

How is the dosage of Egrifta?Egrifta is available in 1 dosages, including 2 mg Injection

What does Egrifta treat?Egrifta treats HIV-Associated Lipodystrophy Syndrome

What is Egrifta made of?Egrifta contains tesamorelin which is a Growth Hormone Releasing Factor Analog

How Is Egrifta Administered?Egrifta is administered as a Injectable

FAQ Data Source

Egrifta

Dosage & administration

drug label

Egrifta prescribing information

prior authorization

Egrifta prior authorization resources

Most recent Egrifta prior authorization forms

Benefits investigation

financial assistance

Egrifta financial assistance options

Co-pay savings program

patient education

Egrifta patient education

Getting started on Egrifta

Patient toolkit

people also ask

Egrifta FAQs